Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Blood (2023) 142 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2023-179174

Published: 2023

Journal Articles

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Blood (2023) 142 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2023-179171

Published: 2023

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Angel Serna, Victor Navarro Garces, Ana Jimenez Ubieto, Evelyn Valencia, Alberto Lopez Garcia, Itziar Carro, Sergi Camarillas, Josu Iraola, Lucia Medina, Gala Vega, Maria Pozas, Anna Maria Sureda Balari, Raul Cordoba, Miguel Canales, Francesc Bosch, Pere Barba, Pau Abrisqueta Costa

Blood (2023) 142 (Supplement 1): 310.

https://doi.org/10.1182/blood-2023-184883

Published: 2023

Journal Articles

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Blood (2023) 142 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2023-186072

Published: 2023

Journal Articles

Incidence, Risk Factors and Clinical Impact of Sars-Cov-2 Prolonged Viral Shedding in Patients Diagnosed with Hematologic Malignancies

Blood (2023) 142 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2023-191146

Published: 2023

Journal Articles

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Blood (2023) 142 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2023-186101

Published: 2023

Journal Articles

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Blood (2023) 142 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2023-181628

Published: 2023

Journal Articles

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Antonieta Molero Yordi, Soraya Peralta Garzón, Laura Gallur, Barbara Tazon, Daniel Medina, Victor Navarro Garces, Maria Julia Montoro, Silvia Saumell, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso Pierola, Felipe Prosper, Maria Diez-Campelo, Olga Salamero, Ana Pérez González, Sara Garrido Paniagua, David Valcarcel

Blood (2023) 142 (Supplement 1): 6457.

https://doi.org/10.1182/blood-2023-185616

Published: 2023

Journal Articles

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Blood (2023) 142 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2023-189503

Published: 2023

Journal Articles

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Soraya Peralta, Laura Gallur, Bárbara Tazón, Víctor Navarro Garcés, Silvia Saumell, Maria Julia Montoro, Olga Salamero, Ana Pérez González, Sara Garrido, Maria Sola, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso-Pierola, Lídia Altimiras, Maria Diez-Campelo, Felipe Prosper, David Valcárcel

Blood (2022) 140 (Supplement 1): 4024–4025.

https://doi.org/10.1182/blood-2022-163188

Published: 2022

Journal Articles

Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic

Blood (2022) 140 (Supplement 1): 2628–2630.

https://doi.org/10.1182/blood-2022-169321

Published: 2022

Journal Articles

Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 1592–1594.

https://doi.org/10.1182/blood-2022-169783

Published: 2022

Journal Articles

PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Pere Barba, Marta Ligero, Cecilia Carpio, Maria Balaguer, Víctor Navarro Garcés, Sabela Bobillo, Francisco Beas, Pau Abrisqueta, Roser Sala, Francesc Bosch, Gloria Iacoboni, Marc Simo, Raquel Perez-Lopez

Blood (2022) 140 (Supplement 1): 3783–3784.

https://doi.org/10.1182/blood-2022-167172

Published: 2022

Journal Articles

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 378–380.

https://doi.org/10.1182/blood-2022-169219

Published: 2022

Journal Articles

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Blood (2022) 140 (Supplement 1): 9335–9337.

https://doi.org/10.1182/blood-2022-163180

Published: 2022

Journal Articles

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Blood (2022) 140 (Supplement 1): 7631–7633.

https://doi.org/10.1182/blood-2022-167747

Published: 2022

Journal Articles

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Marc Bosch Schips, Julia Montoro, Félix López Cadenas, Alba Mesa, Víctor Navarro Garcés, Ana Pérez, Laura Gallur, Silvia Saumell, Mayda Navarrete, Margarita Ortega, Bárbara Tazón, Antonieta Molero, Olga Salamero, Sandra Novoa Jáuregui, Sofia Laura Muzio, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 12308–12310.

https://doi.org/10.1182/blood-2022-157434

Published: 2022

NARROW

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Incidence, Risk Factors and Clinical Impact of Sars-Cov-2 Prolonged Viral Shedding in Patients Diagnosed with Hematologic Malignancies

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic

Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only